Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.11 Average Price Target from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $17.11.

ATEC has been the topic of a number of recent research reports. Barclays upped their price target on shares of Alphatec from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Tuesday, November 19th. Lake Street Capital reduced their target price on shares of Alphatec from $32.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, September 3rd. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Needham & Company LLC reissued a "buy" rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Magnetar Financial LLC bought a new position in Alphatec during the 2nd quarter worth about $10,957,000. First Eagle Investment Management LLC bought a new stake in shares of Alphatec in the 2nd quarter valued at about $1,071,000. Lighthouse Investment Partners LLC boosted its holdings in shares of Alphatec by 257.5% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company's stock valued at $2,180,000 after buying an additional 150,244 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock valued at $16,280,000 after buying an additional 297,850 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Alphatec in the 3rd quarter valued at about $2,057,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Price Performance

Alphatec stock traded up $0.05 during mid-day trading on Wednesday, reaching $10.05. 1,598,944 shares of the company's stock traded hands, compared to its average volume of 1,944,198. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -7.81 and a beta of 1.38. The stock has a 50 day moving average of $7.29 and a two-hundred day moving average of $8.16. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a 12-month low of $4.88 and a 12-month high of $17.34.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.